Infections in patients with chronic lymphocytic leukemia

被引:7
作者
Guarana, Mariana [1 ]
Nucci, Marcio [1 ,2 ,3 ]
机构
[1] Univ Fed Rio de Janeiro UFRJ, Rio De Janeiro, RJ, Brazil
[2] Grp Oncoclin, Rio De Janeiro, RJ, Brazil
[3] Hosp Univ Clementino Fraga Filho, Rua Rodolpho Paulo Rocco 255 Sala 4A 12, BR-21941913 Rio De Janeiro, Brazil
关键词
Chronic lymphocytic leukemia; Leukemia; Chronic lymphoid leukemia; Infection; Immunity; LONG-TERM; RITUXIMAB; FLUDARABINE; COMPLICATIONS; THERAPY; PHASE-3;
D O I
10.1016/j.htct.2023.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Infection is a major complication in patients with chronic lymphocytic leukemia (CLL). Newly diagnosed patients are at high risk of developing infection caused by encapsulated bacteria, such as Streptococcus pneumoniae and Haemophylus influenzae. Method and Results: However, once treatment is initiated, the spectrum of pathogens causing infection broadens, depending on the treatment regimens. With disease progression, cumulative immunosuppression occurs as a consequence of multiple treatment lines and the risk of infection further increases. On the other hand, the use of targeted therapies in the treatment of CLL have brought new risks of infection, with an increased incidence of invasive fungal diseases, particularly aspergillosis, in patients receiving Bruton kinase inhibitors.Conclusion: In this article, we review the epidemiology of infection in patients with CLL, taking into account the treatment regimen, and briefly discuss the management of infection.& COPY; 2023 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:387 / 393
页数:7
相关论文
共 61 条
[1]  
AbadS GyanE, 2003, ClinInfectDis, V37, P27
[2]   Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis [J].
Aksoy, Sercan ;
Dizdar, Oemer ;
Hayran, Mutlu ;
Harputluoglu, Hakan .
LEUKEMIA & LYMPHOMA, 2009, 50 (03) :357-365
[3]   LISTERIOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA WHO WERE TREATED WITH FLUDARABINE AND PREDNISONE [J].
ANAISSIE, E ;
KONTOYIANNIS, DP ;
KANTARJIAN, H ;
ELTING, L ;
ROBERTSON, LE ;
KEATING, M .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (06) :466-469
[4]   Infections in patients with chronic lymphocytic leukemia treated with fludarabine [J].
Anaissie, EJ ;
Kontoyiannis, DP ;
O'Brien, S ;
Kantarjian, H ;
Robertson, L ;
Lerner, S ;
Keating, MJ .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) :559-566
[5]   Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [J].
Benjamini, Ohad ;
Rokach, Lior ;
Itchaki, Gilad ;
Braester, Andrei ;
Shvidel, Lev ;
Goldschmidt, Neta ;
Shapira, Shirley ;
Dally, Najib ;
Avigdor, Abraham ;
Rahav, Galia ;
Lustig, Yaniv ;
Ben David, Shirley Shapiro ;
Fineman, Riva ;
Paz, Alona ;
Bairey, Osnat ;
Polliack, Aaron ;
Levy, Ilana ;
Tadmor, Tamar .
HAEMATOLOGICA, 2022, 107 (03) :625-634
[6]   Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].
Burger, J. A. ;
Tedeschi, A. ;
Barr, P. M. ;
Robak, T. ;
Owen, C. ;
Ghia, P. ;
Bairey, O. ;
Hillmen, P. ;
Bartlett, N. L. ;
Li, J. ;
Simpson, D. ;
Grosicki, S. ;
Devereux, S. ;
McCarthy, H. ;
Coutre, S. ;
Quach, H. ;
Gaidano, G. ;
Maslyak, Z. ;
Stevens, D. A. ;
Janssens, A. ;
Offner, F. ;
Mayer, J. ;
O'Dwyer, M. ;
Hellmann, A. ;
Schuh, A. ;
Siddiqi, T. ;
Polliack, A. ;
Tam, C. S. ;
Suri, D. ;
Cheng, M. ;
Clow, F. ;
Styles, L. ;
James, D. F. ;
Kipps, T. J. ;
Keating, Michael ;
Jen, Jie ;
Jindra, Pavel ;
Simkovic, Martin ;
Braester, Andrei ;
Ruchlemer, Rosa ;
Foa, Roberto ;
Semenzato, Gianpietro ;
Hawkins, Timothy ;
Atanasio, Carolina Moreno ;
Demirkan, Fatih ;
Kaynar, Leylagul ;
Pylypenko, Halyna ;
Fox, Christopher ;
Thirman, Michael ;
Campbell, Philip .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437
[7]   Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy [J].
Burger, Jan A. ;
O'Brien, Susan .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) :510-527
[8]   Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].
Byrd, J. C. ;
Brown, J. R. ;
O'Brien, S. ;
Barrientos, J. C. ;
Kay, N. E. ;
Reddy, N. M. ;
Coutre, S. ;
Tam, C. S. ;
Mulligan, S. P. ;
Jaeger, U. ;
Devereux, S. ;
Barr, P. M. ;
Furman, R. R. ;
Kipps, T. J. ;
Cymbalista, F. ;
Pocock, C. ;
Thornton, P. ;
Caligaris-Cappio, F. ;
Robak, T. ;
Delgado, J. ;
Schuster, S. J. ;
Montillo, M. ;
Schuh, A. ;
de Vos, S. ;
Gill, D. ;
Bloor, A. ;
Dearden, C. ;
Moreno, C. ;
Jones, J. J. ;
Chu, A. D. ;
Fardis, M. ;
McGreivy, J. ;
Clow, F. ;
James, D. F. ;
Hillmen, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223
[9]   Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [J].
Byrd, John C. ;
Hillmen, Peter ;
Ghia, Paolo ;
Kater, Arnon P. ;
Chanan-Khan, Asher ;
Furman, Richard R. ;
O'Brien, Susan ;
Yenerel, Mustafa Nuri ;
Illes, Arpad ;
Kay, Neil ;
Garcia-Marco, Jose A. ;
Mato, Anthony ;
Pinilla-Ibarz, Javier ;
Seymour, John F. ;
Lepretre, Stephane ;
Stilgenbauer, Stephan ;
Robak, Tadeusz ;
Rothbaum, Wayne ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Patel, Priti ;
Higgins, Kara ;
Sohoni, Sophia ;
Jurczak, Wojciech .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) :3441-+
[10]   Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].
Carson, Kenneth R. ;
Evens, Andrew M. ;
Richey, Elizabeth A. ;
Habermann, Thomas M. ;
Focosi, Daniele ;
Seymour, John F. ;
Laubach, Jacob ;
Bawn, Susie D. ;
Gordon, Leo I. ;
Winter, Jane N. ;
Furman, Richard R. ;
Vose, Julie M. ;
Zelenetz, Andrew D. ;
Mamtani, Ronac ;
Raisch, Dennis W. ;
Dorshimer, Gary W. ;
Rosen, Steven T. ;
Muro, Kenji ;
Gottardi-Littell, Numa R. ;
Talley, Robert L. ;
Sartor, Oliver ;
Green, David ;
Major, Eugene O. ;
Bennett, Charles L. .
BLOOD, 2009, 113 (20) :4834-4840